In the UK, the strength of the Tenofovir is listed as 245mg Tenofovir Disoproxil which is equivalent to 300mg of Tenofovir Disoproxil Fumarate. The strength of 245mg Tenofovir in the UK is the same as 300mg listed in the US product. The medicine is exactly the same dosage as the US product.
Information about Stribild (Elvitegravir / Cobicistat / Emtricitabine / Tenofovir)
Stribild is a combination medication used to treat HIV (Human Immunodeficiency Virus) infection in adults. It combines four active ingredients—Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir disoproxil fumarate—into a single tablet for convenience. The combination of these ingredients helps reduce the HIV viral load and prevents the progression of HIV by interfering with different stages of the virus's life cycle. Stribild is often prescribed as part of a complete antiretroviral therapy (ART) regimen for people with HIV.
Product Highlights
- It is used as a combination antiretroviral therapy (ART) for the treatment of HIV-1 infection in adults who have not previously been treated with HIV medicines or who have a history of treatment failure.
- This means it can be prescribed to adults who have not yet started antiretroviral therapy.
Key Ingredients
- Elvitegravir
- Cobicistat
- Emtricitabine
- Tenofovir Disoproxil Fumarate
Key Benefits
- Stribild effectively suppresses the HIV virus, reducing the viral load in the blood and improving immune function.
- By combining four medications into one tablet, Stribild simplifies treatment adherence for patients.
- Each ingredient targets a different stage of the HIV life cycle, offering a comprehensive approach to treatment.
- Stribild is taken once daily, which helps improve patient compliance with treatment regimens.
Direction of Use
- Stribild is taken orally as a tablet.
- The typical dose is one tablet once a day with food. It is important to follow the prescribed schedule and take the medication at the same time each day to maximize effectiveness.
- Take Stribild with food to ensure proper absorption and minimize potential gastrointestinal side effects.
- If you miss a dose, take it as soon as possible, unless it's nearly time for your next dose. Do not take two doses at once.
Safety Concerns
- Stribild can cause kidney problems, including kidney damage or worsening of kidney disease. Kidney function should be monitored during treatment, especially in patients with pre-existing kidney conditions.
- Long-term use of Tenofovir may affect bone mineral density, increasing the risk of bone fractures. Monitoring bone health may be necessary.
- Patients with liver disease or hepatitis B may experience liver-related side effects. Liver function should be regularly monitored throughout the treatment.
- Cobicistat, an ingredient in Stribild, can interact with other medications. Notify your healthcare provider of all the medications you are taking to prevent potential drug interactions.
- Rare hypersensitivity reactions have been reported, and patients should seek immediate medical attention if they experience symptoms like rash, fever, or difficulty breathing.
Avoid Stribild (Elvitegravir / Cobicistat / Emtricitabine / Tenofovir) If
- Stribild should not be used in patients with severe renal impairment (CrCl < 70 mL/min).
- Patients with severe liver impairment (Child-Pugh Class C) should not use Stribild.
- Stribild should not be used in the first trimester of pregnancy unless absolutely necessary, as the effects on the developing fetus are not fully known.
- If a patient has a known allergy to any of the components of Stribild (Elvitegravir, Cobicistat, Emtricitabine, or Tenofovir), the medication should be avoided.
- Stribild should not be used with other products containing any of its components (Elvitegravir, Cobicistat, Emtricitabine, or Tenofovir) to avoid potential overdose or drug interactions.
